Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 5/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.32 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.32 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412629 | 1.00 | SLC6A11 (0.36) | SLC6A11SLC6A1KIF11TYMPMEN1 | |
| SCHEMBL6406883 | 0.84 | SLC6A11 (0.39) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL6409595 | 0.84 | SLC6A11 (0.39) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL6481384 | 0.81 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11TYMPMEN1 | |
| SCHEMBL6410799 | 0.81 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11TYMPMEN1 | |
| SCHEMBL6408185 | 0.81 | SLC6A11 (0.41) | SLC6A11SLC6A1KIF11TYMPMEN1 | |
| SCHEMBL6406914 | 0.81 | SLC6A11 (0.41) | SLC6A11SLC6A1KIF11MEN1TP53 | |
| SCHEMBL6406931 | 0.81 | SLC6A11 (0.41) | SLC6A11SLC6A1KIF11TYMPMEN1 | |
| SCHEMBL6408331 | 0.81 | TSPO (0.36) | TNFRSF1A | |
| SCHEMBL6412775 | 0.81 | SLC6A11 (0.36) | SLC6A11SLC6A1MEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | SUMITOMO CHEMICAL COMPAY LIMTED (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1538141-A1 | PROCESS FOR PRODUCTION OF 2-(HYDROXYMETHYL)CYCLO- PROPANECARBOXYLIC ACIDS | Sumitomo Chemical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | GRHPR, PCCA, C5 | SLC6A11 2935/4885SLC6A1 2874/4885KIF11 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.